tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SPRY Stock Latest News

ARS Pharmaceuticals announces California eligible for neffyinSchools program
The FlyARS Pharmaceuticals announces California eligible for neffyinSchools program
12d ago
SPRY
ARS Pharmaceuticals: Buy Rating Reaffirmed on Improved Competitive Outlook After Aquestive’s Anaphylm Setback
PremiumRatings
ARS Pharmaceuticals: Buy Rating Reaffirmed on Improved Competitive Outlook After Aquestive’s Anaphylm Setback
23d ago
SPRY
Regulatory Setbacks for Anaphylm Enhance ARS Pharmaceuticals’ Competitive Position and Support SPRY Buy Rating
PremiumRatings
Regulatory Setbacks for Anaphylm Enhance ARS Pharmaceuticals’ Competitive Position and Support SPRY Buy Rating
23d ago
SPRY
ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James
PremiumThe Fly
ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James
23d ago
AQST
SPRY
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg
PremiumThe Fly
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg
1M ago
SPRY
ARS Pharmaceuticals: Strategic Positioning and Market Potential for Neffy Justifies Buy Rating
PremiumRatingsARS Pharmaceuticals: Strategic Positioning and Market Potential for Neffy Justifies Buy Rating
2M ago
SPRY
ARS Pharmaceuticals management to meet with Oppenheimer
Premium
The Fly
ARS Pharmaceuticals management to meet with Oppenheimer
3M ago
SPRY
ARS Pharmaceuticals price target lowered to $35 from $40 at Oppenheimer
Premium
The Fly
ARS Pharmaceuticals price target lowered to $35 from $40 at Oppenheimer
3M ago
SPRY
ARS Pharmaceuticals Reports Strong Q3 2025 Growth
PremiumCompany Announcements
ARS Pharmaceuticals Reports Strong Q3 2025 Growth
3M ago
SPRY
Ars Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
Ars Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
3M ago
SPRY
Promising Outlook for ARS Pharmaceuticals: Buy Rating Affirmed by Lachlan Hanbury Brown
PremiumRatings
Promising Outlook for ARS Pharmaceuticals: Buy Rating Affirmed by Lachlan Hanbury Brown
3M ago
SPRY
ARS Pharmaceuticals Reports Q3 2025 Financial Results
PremiumCompany Announcements
ARS Pharmaceuticals Reports Q3 2025 Financial Results
3M ago
8K
SPRY
ARS Pharmaceuticals reports Q3 EPS (52c), consensus (49c)
PremiumThe FlyARS Pharmaceuticals reports Q3 EPS (52c), consensus (49c)
3M ago
SPRY
SPRY Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
SPRY Earnings this Week: How Will it Perform?
3M ago
SPRY
DraftKings, Flutter downgraded: Wall Street’s top analyst calls
Premium
The Fly
DraftKings, Flutter downgraded: Wall Street’s top analyst calls
3M ago
CV
WM
ARS Pharmaceuticals launches ‘Get neffy on Us’
PremiumThe Fly
ARS Pharmaceuticals launches ‘Get neffy on Us’
3M ago
SPRY
ARS Pharmaceuticals resumed with a Buy at Roth Capital
PremiumThe Fly
ARS Pharmaceuticals resumed with a Buy at Roth Capital
3M ago
SPRY
Ars Pharmaceuticals’ Latest Study: A Potential Game-Changer in Allergy Treatment
PremiumCompany Announcements
Ars Pharmaceuticals’ Latest Study: A Potential Game-Changer in Allergy Treatment
3M ago
SPRY
Ars Pharmaceuticals’ Promising Study on ARS-2 for Chronic Urticaria: What Investors Need to Know
PremiumCompany Announcements
Ars Pharmaceuticals’ Promising Study on ARS-2 for Chronic Urticaria: What Investors Need to Know
3M ago
SPRY
ARS Pharmaceuticals receives favorable decision from EPO on neffy
PremiumThe FlyARS Pharmaceuticals receives favorable decision from EPO on neffy
4M ago
SPRY
ARS Pharmaceuticals: Strategic Financial Maneuvers and Market Potential Drive Buy Rating
Premium
Ratings
ARS Pharmaceuticals: Strategic Financial Maneuvers and Market Potential Drive Buy Rating
4M ago
SPRY
ARS Pharmaceuticals Secures $250 Million Credit Agreement
Premium
Company Announcements
ARS Pharmaceuticals Secures $250 Million Credit Agreement
4M ago
8K
SPRY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >